Ravi Viswanathan insider trades: PhaseBio Pharmaceuticals (PHAS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ravi reports to the SEC
and 28 more companies
Open-market buys and sales
55 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 22, 2018 | PHAS | ↑ Buy | 1,800,000 | $5.00 | $9.0M | See Note 2 | Oct 24, 2018 (2d) |
| Sep 7, 2018 | ADAP | ↑ Buy | 12,000,000 | $1.67 | $20.0M | See Note 5 | Sep 10, 2018 (3d) |
| Sep 7, 2018 | ADAP | ↑ Buy | 3,000,000 | $1.67 | $5.0M | See Note 3 | Sep 10, 2018 (3d) |
| Aug 21, 2018 | AVEO | ↑ Buy | 663,716 | $2.26 | $1.5M | See Note 1 | Aug 22, 2018 (1d) |
| Jul 19, 2018 | AVEO | ↑ Buy | 250,600 | $1.96 | $492K | See Note 2 | Jul 20, 2018 (1d) |
| Jun 28, 2018 | AVEO | ↑ Buy | 192,425 | $2.10 | $404K | See Note 1 | Jun 28, 2018 (0d) |
| May 30, 2018 | AVEO | ↑ Buy | 275 | $2.15 | $591 | See Note 1 | May 30, 2018 (0d) |
| May 21, 2018 | AVEO | ↑ Buy | 236,479 | $2.13 | $503K | See Note 2 | May 21, 2018 (0d) |
| May 8, 2018 | AVEO | ↑ Buy | 70,873 | $2.13 | $151K | See Note 2 | May 10, 2018 (2d) |
| Apr 23, 2018 | SURF | ↑ Buy | 133,333 | $15.00 | $2.0M | See Note 2 | Apr 23, 2018 (0d) |
| Apr 10, 2018 | AVEO | ↑ Buy | 920,976 | $2.30 | $2.1M | See Note 2 | Apr 10, 2018 (0d) |
| Mar 27, 2018 | ADAP | ↑ Buy | 6,571,164 | $1.92 | $12.6M | See Note 3 | Mar 28, 2018 (1d) |
| Mar 27, 2018 | TCON | ↑ Buy | 707,964 | $2.70 | $1.9M | See Note 2 | Mar 27, 2018 (0d) |
| Mar 23, 2018 | ADAP | ↑ Buy | 1,268,508 | $1.91 | $2.4M | See Note 3 | Mar 23, 2018 (0d) |
| Mar 6, 2018 | TSRO | ↑ Buy | 116,445 | $57.40 | $6.7M | See Note 2 | Mar 6, 2018 (0d) |
| Mar 6, 2018 | TSRO | ↑ Buy | 29,087 | $57.40 | $1.7M | See Note 11 | Mar 6, 2018 (0d) |
| Feb 26, 2018 | ABIO | ↓ Sell | 1,460,209 | $0.50 | $731K | See Note 2 | Feb 27, 2018 (1d) |
| Feb 16, 2018 | RARX | ↑ Buy | 2,000,000 | $6.00 | $12.0M | Direct | Feb 21, 2018 (5d) |
| Nov 27, 2017 | APPN | ↓ Sell | 569,620 | $19.49 | $11.1M | See Note 4 | Nov 27, 2017 (0d) |
| Nov 20, 2017 | APPN | ↓ Sell | 2,820,516 | $19.49 | $55.0M | See Note 4 | Nov 21, 2017 (1d) |
| Oct 10, 2017 | RYTM | ↑ Buy | 550,000 | $17.00 | $9.3M | See Note 2 | Oct 10, 2017 (0d) |
| Jul 3, 2017 | MRSN | ↑ Buy | 1,000,000 | $15.00 | $15.0M | See Note 3 | Jul 6, 2017 (3d) |
| Mar 28, 2017 | AVEO | ↑ Buy | 6,000,000 | $0.50 | $3.0M | See Note 2 | Mar 29, 2017 (1d) |
| Mar 27, 2017 | ADAP | ↑ Buy | 12,870,000 | $0.70 | $9.0M | See Note 3 | Mar 28, 2017 (1d) |
| Dec 19, 2016 | AKAO | ↑ Buy | 500,000 | $13.50 | $6.8M | See Note 1 | Dec 19, 2016 (0d) |
| Nov 29, 2016 | TCON | ↑ Buy | 869,565 | $5.75 | $5.0M | See Note 1 | Nov 29, 2016 (0d) |
| Oct 31, 2016 | RARX | ↑ Buy | 338,462 | $13.00 | $4.4M | See Note 2 | Oct 31, 2016 (0d) |
| Oct 31, 2016 | RARX | ↓ Sell | 435 | $13.00 | $6K | See Note 2 | Oct 31, 2016 (0d) |
| Jul 29, 2016 | ILIU | ↑ Buy | 20,120,724 | $0.10 | $2.0M | See Note 1 | Aug 2, 2016 (4d) |
| Jul 18, 2016 | ARDX | ↑ Buy | 763,651 | $8.73 | $6.7M | See Note 2 | Jul 20, 2016 (2d) |
| Jul 18, 2016 | ARDX | ↑ Buy | 763,650 | $8.73 | $6.7M | See Note 3 | Jul 20, 2016 (2d) |
| Mar 18, 2016 | TSRO | ↑ Buy | 710,429 | $35.19 | $25.0M | See Note 3 | Mar 18, 2016 (0d) |
| Mar 18, 2016 | TSRO | ↑ Buy | 710,429 | $35.19 | $25.0M | See Note 2 | Mar 18, 2016 (0d) |
| Jan 13, 2016 | ARDX | ↑ Buy | 500,000 | $10.00 | $5.0M | See Note 3 | Jan 14, 2016 (1d) |
| Jan 13, 2016 | ARDX | ↑ Buy | 500,000 | $10.00 | $5.0M | See Note 2 | Jan 14, 2016 (1d) |
| Jan 12, 2016 | EPZM | ↑ Buy | 1,111,111 | $9.00 | $10.0M | See Note 2 | Jan 12, 2016 (0d) |
| Oct 6, 2015 | MIRN | ↑ Buy | 857,142 | $7.00 | $6.0M | See Note 2 | Oct 6, 2015 (0d) |
| Jun 15, 2015 | TSRO | ↓ Sell | 889 | $54.80 | $49K | See Note 2 | Jun 15, 2015 (0d) |
| Feb 4, 2015 | TCON | ↑ Buy | 500,000 | $10.00 | $5.0M | See Note 2 | Feb 5, 2015 (1d) |
| Dec 23, 2014 | ILIU | ↑ Buy | 19,868,965 | $0.10 | $2.0M | See Note 1 | Dec 29, 2014 (6d) |
| Oct 8, 2014 | DERM | ↑ Buy | 69,112 | $16.00 | $1.1M | See Note 2 | Oct 8, 2014 (0d) |
| Aug 18, 2014 | EPZM | ↓ Sell | 433 | $35.56 | $15K | See Note 7 | Aug 18, 2014 (0d) |
| Aug 18, 2014 | CVT | ↓ Sell | 336 | $26.04 | $9K | See Note 7 | Aug 18, 2014 (0d) |
| Aug 6, 2014 | LOXO | ↑ Buy | 230,769 | $13.00 | $3.0M | See Note 2 | Aug 6, 2014 (0d) |
| Jul 22, 2014 | ROKA | ↑ Buy | 383,333 | $12.00 | $4.6M | See Note 1 | Jul 22, 2014 (0d) |
| Jan 21, 2014 | CVT | ↓ Sell | 169,887 | $35.50 | $6.0M | See Note 1 | Jan 23, 2014 (2d) |
| Jan 16, 2014 | CVT | ↓ Sell | 1,132,589 | $35.50 | $40.2M | See Note 1 | Jan 21, 2014 (5d) |
| Jan 15, 2014 | GLYC | ↑ Buy | 512,500 | $8.00 | $4.1M | Direct | Jan 15, 2014 (0d) |
| Nov 15, 2013 | EPZM | ↑ Buy | 406,500 | $19.68 | $8.0M | See Note 2 | Nov 18, 2013 (3d) |
| Jun 5, 2013 | EPZM | ↑ Buy | 400,000 | $15.00 | $6.0M | See Note 2 | Jun 7, 2013 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Ravi Viswanathan's insider trades
Ravi Viswanathan is a 10% owner of PhaseBio Pharmaceuticals (PHAS). Since Nov 21, 2011, Ravi has reported 44 open-market purchases worth $293.2M and 11 sales worth $134.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include conversions (32 filings), other transactions (23 filings), grants and awards (4 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PHAS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.